Last updated on July 2019

The Safety Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors


Brief description of study

The Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors

Clinical Study Identifier: NCT02660034

Find a site near you

Start Over

Pinnacle Oncology Hematology

Scottsdale, AZ United States
  Connect »

Cedars Sinai Medical Center

Los Angeles, CA United States
  Connect »

Fox Chase Cancer Center

Philadelphia, PA United States
  Connect »

Texas Oncology

Dallas, TX United States
  Connect »

Texas Oncology

Tyler, TX United States
  Connect »

Virginia Cancer Specialists

Fairfax, VA United States
  Connect »

Westmead Hospital

Parramatta, Australia
  Connect »

Prince of Wales

Randwick, Australia
  Connect »

Icon Cancer Care

Brisbane, Australia
  Connect »

Monash Health

Clayton, Australia
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.